AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03415386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of antiplatelet drugs and anticoagulants for at least one month
Description: Combination of antiplatelet drugs and anticoagulants for at least one month, such as aspirin100mg qd+clopidogrel75mg qd+warfarin (INR1.8-2.2), aspirin100mg qd+clopidogrel75mg qd+dabigatran110mg bid, aspirin100mg qd+ticagrelor60mg bid+warfarin (INR1.8-2.2), and aspirin100mg qd+ticagrelor60mg bid+dabigatran110mg bid. Transthoracic two-dimensional echocardiography will be done at the 1-month, 3-month and 6-month follow-ups to evaluate the left ventricular mural thrombus and determinate whether the antithrombotic therapy regimen could be regulated to double antiplatelet or anticoagulant+clopidogrel75mg qd/ticagrelor60mg bid.
Study NCT02325843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: human bone marrow MSC
Description: The arms of active comparator :human bone marrow MSC subconjunctival injection once time. If persistent epithelial defect was noted thereafter, a second MSC injection was performed.
Study NCT01517971 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01715129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin Pamoate 11.25mg
Study NCT02285179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: daily dose of 20 mg
Study NCT02285179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tamoxifen
Description: daily dose of 20 mg
Study NCT03677193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Playing ICP game
Description: Participants will play the ICP game from their home this is expected to be 30 min \* 5 days / week for 4 weeks. Once per week, participants will play the ICP game with a researcher.
Study NCT02452333 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oncoplastic Approach Excisional Breast Biopsy
Description: Evidence based quadrant by quadrant oncoplastic algorithm reinforced with videoscopic applications for peripheral lesions.
Study NCT02452333 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Excisional Breast Biopsy
Description: Conventional Excisional Breast Biopsy
Study NCT02452333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tezel Method of Breast Volume Measurement
Description: Tezel Method is a simple, accurate and non-invasive method of measuring differences in breast volume based on Archimedes' principle
Study NCT02452333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cosmetic Assessment
Description: Cosmetic Assessment with Harris scale graded by patient, surgeon and professional third party. A standardised photograph of front, side and mediolateral oblique views will be taken using a digital camera for professional third party observers.
Study NCT03069651 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Virtual Care
Description: The use of Videoconferencing software to enable remote access to monitor patients in the 'Virtual Care' cohort.
Study NCT03069651 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Care
Description: The use of Videoconferencing software to enable remote access to monitor patients in the 'Virtual Care' cohort.
Study NCT03900195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BottlePEP
Description: Positive expiratory device with a bottle
Study NCT04824378 — intervention group
Intervention type: OTHER
Intervention: No Intervention.
Description: No Intervention.Only learn ICG image features of different label groups
Study NCT00239031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-Coated Mycophenolate Sodium
Description: Enteric-Coated Mycophenolate Sodium
Study NCT02087332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolonged release Torasemide (Britomar)
Study NCT02087332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Torasemide (Diuver)
Study NCT02151513 — intervention group
Intervention type: DEVICE
Intervention: Intrathecal Pump Placement
Study NCT01746251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Afatinib
Study NCT05895916 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-volume road cycling
Description: 1,144 km of road cycling performed on seven consecutive days with an increase in energy intake to maintain a stable body weight
Study NCT01615497 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment as Usual (TAU)
Description: Treatment normally offered at this clinic which could include individual or group alcohol and drug counseling sessions one time per week lasting one hour each time.
Study NCT01549301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: filgrastim, single dose, s.c., dosage: 5 mcg/kg
Study NCT01549301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: filgrastim, single dose, s.c., dosage: 10 mcg/kg
Study NCT01549301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim, i.v., single dose, dosage: 5 mcg/kg
Study NCT01549301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim, i.v., single dose, dosage: 10 mcg/kg
Study NCT04256967 — intervention group
Intervention type: OTHER
Intervention: Body and health focused study environment
Description: Students are exposed to lectures, literature, co-students, contexts that provide body and lifestyle awareness beyond the existing exposure of the society in general
Study NCT00624221 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Descemet's stripping endothelial keratoplasty
Description: Small incision corneal transplant procedure to treat dysfunctional endothelium.
Study NCT03592459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macy Catheter
Description: Undergo placement of Macy catheter
Study NCT03592459 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pain Therapy
Description: Receive opioids via Macy catheter
Study NCT03592459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03592459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT00127127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: vorinostat 100 mg, 200 mg, 400 mg, or 500 mg single oral dose; once-daily or twice-daily administration
Study NCT00935883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eculizumab
Description: Induction Period: patient will receive eculizumab 600 mg or 900 mg via IV infusion over approximately 30 minutes once a week (7 ± 2 days) for 4 weeks followed by 900 mg or 1200 mg eculizumab for the fifth dose 7 days later (7 ± 2 days).~Maintenance Period: patient will receive eculizumab 900 mg or 1200 mg via IV infusion over approximately 30 minutes every 2 weeks (14 ± 2 days) until week 24.~Observation period: patient will then be observed for 6 months off treatment with follow-up visits scheduled for 9 months and 12 months.
Study NCT00935883 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Induction Period: patient will receive saline via IV infusion over approximately 30 minutes once a week (7 ± 2 days) for 4 weeks followed by saline for the fifth dose 7 days later (7 ± 2 days).~Maintenance Period: patient will receive saline via IV infusion over approximately 30 minutes every 2 weeks (14 ± 2 days) until week 24.~Observation period: patient will then be observed for 6 months off treatment with follow-up visits scheduled for 9 months and 12 months.
Study NCT03396328 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional low salt education
Description: conventional low salt education
Study NCT03396328 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive low salt dietary education by smartphone application
Description: Participants are provided with information on food and recipe, which allows them to record daily meals in their applications. Through the mobile application, the participants receive information on daily salt intake. Based on this information, the clinical nutritionist coach sets a goal for low salt diet and provides feedback to the patients through the mobile application. The clinical nutritionist coach checks the activity of the user more than twice a week and sends in-app messages to maintain compliance.
Study NCT01974817 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent conjugate pneumococcal vaccine
Description: 0.5ml IM for one dose
Study NCT03195894 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TripleA
Study NCT03593915 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine
Description: PHASE 1b:~Decitabine administered as an intravenous (IV) infusion daily for 5 days at a dose of 20 mg/m2 followed on Day 8 by alvocidib as a loading dose over 30 minutes followed by a 4-hour IV infusion (hybrid dosing) Once the maximum dose of alvocidib administered via hybrid dosing has been determined, 2 cohorts of patients will receive azacitidine followed by alvocidib administered as an IV infusion. Azacitidine may be administered as either an IV bolus over 10 to 40 minutes or as a subcutaneous (SC) injection on either a 7 day or 5-2 2 schedule. Regardless of which azacitidine schedule or route of administration is used, alvocidib will be given on Day 10 as a 30-to-60 minute IVI~PHASE 2:~The Phase 2 study will use the RP2D from the Phase 1b study and follow a Simon 2-stage minimax design using the RP2D of alvocidib administered as a 30-to-60 minute IV infusion determined in the Ph1b study to explore efficacy of alvocidib when administered in sequence after azacitidine.
Study NCT01991561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose of H5 VLP vaccine + Alhydrogel
Description: Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with Alhydrogel
Study NCT01991561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Med dose of H5 VLP vaccine + Alhydrogel
Description: Biological:Med dose of H5 VLP vaccine 2 doses given 21 days apart of Med dose H5 VLP vaccine mixed with Alhydrogel
Study NCT01991561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose of H5 VLP vaccine + Alhydrogel
Description: Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with Alhydrogel
Study NCT01991561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose of H5 VLP vaccine + GLA-SE
Description: Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with GLA-SE
Study NCT01991561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose of H5 VLP vaccine + GLA-SE
Description: Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with GLA-SE
Study NCT01991561 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator: Placebo
Description: Biological: Placebo 2 doses given 21 days apart of the placebo
Study NCT01300104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Prescriptions: Vigorous exercise (average 65-70% of maximal oxygen consumption) minimum 3 times 45 minutes per week according to customized endurance training programs.~Restrictions: None.
Study NCT01300104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole grain rye
Description: Prescriptions: Minimum 170-180g of whole grain rye intake per day. Restrictions: None.
Study NCT01300104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recommendations
Description: Recommendations on a health-promoting, energy restricted diet according to Danish Nutrition Recommendations and encouraged to walk at least 10,000 steps every day.
Study NCT01300104 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recommendations
Description: Recommendations on a health-promoting, energy restricted diet according to Danish Nutrition Recommendations and encouraged to walk at least 10,000 steps every day.
Study NCT01875497 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: grape fruit (vitis vinifera) extract in capsule with 205 mg
Description: Before the exercise the indivuduals intake only one capsule of the grape fruit extract with 205 mg. This dosage is free of contraindications according to others studies.
Study NCT02532231 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02532231 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02935972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam
Description: received intravenous diazepam 5 mg slowly just before TRUS probe insertion
Study NCT02935972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 1%
Description: received 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
Study NCT02935972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam and Lidocaine 1%
Description: received intravenous diazepam 5 mg slowly just before probe insertion and 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
Study NCT04194060 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery after Surgery group
Description: * Tracheal intubation and with General anesthesia~* Short acting anesthetic agents,avoid opioid agents~* Omental patch repair with placement of sub hepatic drain~* Bilateral Transverse abdominis plane block/ Rectus sheath block immediately after surgery.~* Post operative nausea and vomiting prophylaxis.~* Encourage to mobilize out of bed after effect of general anesthesia has weaned off.~* Initiation of feeding-Oral sips on day 1, step up day 2 onward~* Removal of nasogastric tube-immediately after surgery after aspirating the gastric content through nasogastric tube.~* Removal of urinary catheter-after weaning from the effect of general anesthesia.~* Sub hepatic drain removal -anytime within 24 hours;drain will not be removed if fluid is bilious or pus.~* Avoid opiod analgesics.
Study NCT04194060 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Tracheal intubation~* Short acting anesthetic agents, avoid opiod anesthesia agents.~* Omental patch repair along with sub hepatic drain placement.~* Post operative nausea and vomiting prophylaxis.~* Ambulation-as per patients' own request.~* Initiation of oral feed- after passage of 1st flatus.~* Nasogastric tube removal-output \<300ml/day with resolution of ileus.~* Removal of urinary catheter- when patient sits on bed side/ambulate.~* Removal of sub hepatic drain-when patient tolerates unrestricted amount of liquid diet and drain output is less than 200 ml /day.~* Patient will receive opiod analgesics.
Study NCT02144272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3114062 SC
Description: LY3114062 administered SC.
Study NCT02144272 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered SC.
Study NCT02144272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3114062 IV
Description: LY3114062 administered IV.
Study NCT03009604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simethicone
Description: Simethicone 40mg oral tablets
Study NCT03009604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enema
Description: sodium dihydrogen phosphate dihydrate 19.2 gram \& disodium hydrogen phosphate dodecahydrate 7.2 gram, in addition to purified water
Study NCT02420834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose
Description: Tear supplement to be taken as required to relieve symptoms
Study NCT02420834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liposomal Spray
Description: Tear supplement o be taken as required to relieve symptoms
Study NCT03004105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Safety Run-In - Beginning dose is Selumetinib 50 mg by mouth twice a day on Days 1 through 28 of a 28 day cycle~Intermittent Arm - Participants receive Selumetinib at 75 mg by mouth twice a day for 7 days on and 7 days off.~Continuous Arm - Participants take Selumetinib twice daily on Days 1 to 28 of a 28 day cycle. Dose determined by safety run-in.
Study NCT03004105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Safety Run-In, Intermittent Arm, Continuous Arm - Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.
Study NCT03004105 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Calls
Description: About every 6 months, participant called by a member of the study staff to ask how participant is doing and if participant has started any new treatments outside of the study. These calls should last about 10 minutes each time.
Study NCT01110473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-348
Description: An oral dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
Study NCT01110473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-348
Description: An oral dose of ABT-348, twice daily on Day 1, Day 8, and Day 15 of each 28 day cycle
Study NCT01110473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-348 and azacitidine
Description: An oral dose of ABT-348 on Day 1, Day 8, and Day 15 of each 28 day cycle. An IV or injection of azacitidine on Days 1-7 of each 28 day cycle.
Study NCT01110473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-348
Description: An intravenous dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
Study NCT03351335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microfocused ultrasound with visualization
Description: All subjects will receive an Ultherapy® treatment at dual depth using the 4-4.5mm and 7-3.0mm transducers. Treatments will be provided to the lower face, submental (under the chin) and neck area.
Study NCT00890526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sound Therapy (Tinnitus Retraining Therapy)
Description: The conventional sound therapy will be achieved with commercially available noise generators. Our clinic uses General Hearing Instruments (OHI) model Tranquil devices as noise sources for TRT. These flexible devices offer an adjustable volume control, with a frequency response extending from \~500 to 8000 Hz. Matched devices will be fitted binaurally and adjusted to each individual ear to achieve audibility of the noise sources (assessed by slight threshold shifts. typically 10- 15 dB, across the audiometric frequency range above 500 Hz). The sound pressure level output and frequency response of each noise source will be measured and documented using both real ear and standard electroacoustic methodologies. Each subject will be carefully instructed as to care of the instruments and correct volume setting. The bilateral noise generators will be used chronically during the intervention period except during sleep.
Study NCT00890526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling (Tinnitus Retraining Therapy)
Description: The directive counseling to be used will include an in-depth participatory discussion with the patient to review audiometric and functional test results, along with the anatomy and physiology of the auditory system. A minimum of two hours will be scheduled to impart this information to the patients so that they will have a clear understanding of the disorder based upon the most current scientific data. The counseling will be focused on educating the patient, neutralizing their negative emotional association with the hyperacusis, and discussing their treatment.
Study NCT00890526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Counseling
Description: Patients who are enrolled in Arms 3 and 4 of this study will not be offered directive counseling, but will be fitted with either conventional or placebo noise generators for their sound therapy components. These patients will be told only that their treatment for hyperacusis uses sound therapy. Otherwise, in the instrument fitting appointment (either for the conventional instrument or the placebo device), these patients will receive the same instruction in the care and use of sound generators as those patients enrolled in Treatment Arms 1 and 2 of the clinical trial.
Study NCT01185847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5083945
Description: intravenously, until disease progression
Study NCT00890526 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Counseling
Description: Patients who are enrolled in Arms 3 and 4 of this study will not be offered directive counseling, but will be fitted with either conventional or placebo noise generators for their sound therapy components. These patients will be told only that their treatment for hyperacusis uses sound therapy. Otherwise, in the instrument fitting appointment (either for the conventional instrument or the placebo device), these patients will receive the same instruction in the care and use of sound generators as those patients enrolled in Treatment Arms 1 and 2 of the clinical trial.
Study NCT01185847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: standard treatment, up to 6 cycles